We have compiled a list of the 100 most cited researchers in Parkinson's disease since 1985 together with H-Indices as a means to assess productivity and impact. Within the total-citations ranking, "broad impact" citations are used as a way of identifying those researchers whose work is cited widely beyond the Parkinson's disease research community. Finally, we present a table of the most cited researchers this decade for a comparison of the two with analysis.
INTRODUCTION
The number of citations an article receives is widely accepted as a measure of its impact. In recent years, the field of Parkinson's Disease (PD) research has been the focus of two bibliometric studies in which the mosthighly cited papers were identified [1] and a partial ranking of top authors was generated [2] . There has not, however, been a broad analysis of the PD research literature to assess, in a comprehensive manner, the impact and productivity of the top investigators, which this study aims to provide.
METHODS
The following three dimensions were selected as a basis to measure the work in PD by individual * Correspondence to: Aaron A. Sorensen, GE Healthcare, Clinical
Research Industry Specialist, 116 Huntington Avenue, Boston, MA 02116, USA. E-mail: aaron.sorensen@ge.com. investigators: total citations, "broad impact" citations and H-index. Briefly, the H-index is a measure of an author's highly cited body of work rather than of individual papers -for details see [3, 4] . Broad impact citations are a new measure, discussed below. The underlying data used in the tabulation of each dimension originate from Thomson Reuter's ISI Web of Science (WoS).
Two selection filters were used in determining which papers would contribute to an individual scientist's metrics. The first filter was a requirement that all papers to be included in the analysis mention "Parkinson," "Parkinson's," "Parkinsons," "Parkinsonism," or "Parkinsonian" in the title while excluding those papers which contained the term "amyotrophic" in the title field or alternatively "wolff-parkinson-white" in the title, abstract, or keyword fields. The above exclusion criteria were added when it became clear that, without them, a number of papers which are primarily about ALS and Wolff-Parkinson-White syndrome would lessen the accuracy of the analysis through the introduction of data points which are false-positive in nature. The second filter is temporal: only papers ISSN 1877-7171/11/$27.50 © 2011 -IOS Press and the authors. All rights reserved published and subsequently indexed in WoS between 1 January 1985 and 17 February 2011 were considered. We selected this time period because it is one which has seen remarkable progress and yet is still recent enough that almost all of the investigators in the rankings are still alive. It is important to recognize the effects of the temporal filter as researchers who made fundamental contributions to the field prior to 1985 but have since slowed in the areas of impact and productivity will be underrepresented in this study due to the 1985 limitation. Melvin Yahr and Margaret Hoehn, who, in a landmark paper in 1967, introduced what has long been the standard classification system of PD disease progression, are a case in point. Also of importance is the PD-specific filter, as some prominent PD scientists have strong interests in other areas. Their impact and productivity in non-PD fields will not be recognized in this analysis. John Trojanowski, of the University of Pennsylvania, and Maria Grazia Spillantini, of the University of Cambridge, are prime examples of this phenomenon as their research focuses on the mechanisms which underlie a wide range of neurodegenerative disorders.
Continuing along this line of thought, it seems that analyzing only papers with PD in the title may favor articles on translational or clinical studies for the reason that basic scientists studying the mechanisms underlying PD appear to be less apt to include PD in the titles of their papers. As an example, Spillantini and Trojanowski together with collaborators, Marie Luise Schmidt, Virginia M.-Y. Lee, Ross Jakes, and Michel Goedert, wrote a landmark paper published in Nature in 1997 which mentioned PD in the abstract, but not in the title [5] . Entitled, "alpha-synuclein in Lewy bodies", the paper has accumulated 1,945 citations to date which would have made it the third most-cited paper in the current analysis, had it been included. An analysis of the "false positive" papers which would have been included in the study by relaxing the requirement of a PD-specific title, however, led us to the decision to mandate that PD appear in the title in line with previous studies [1] . A first example of a highly-cited paper which might have been included through the employment of a more relaxed search strategy is "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease" [6] , which appeared in Neurology in 1991 and has accumulated 2,444 citations to date. This high-impact AD paper happened to contain PD in its keyword list and is, therefore, returned when one uses the default "Topic" search in WoS. A second example is "Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine" [7] , which appeared in Nature in 1991 and has accumulated 1,708 citations to date. PD is mentioned in the abstract of this paper, and while the dopamine-receptor research described in this paper may have had a sizeable indirect impact in the world of PD research, it is clear that a paper such as this has its "conceptual home" squarely within the world of schizophrenia investigation.
It is interesting to note that the clinical/translational bias observed in the current analysis appears, anecdotally, to be more apparent than that observed in a similar study conducted in the area of Alzheimer's Disease (AD) [8] . When compared to PD, the historic lack of clinical treatment options for people with AD might, in part, explain why the clinical/translational bias is more evident in the PD study. As demonstrated through the example of the alpha-synuclein paper above, another contributing factor could be the stricter requirement in the current study regarding the appearance of the disease in question in the title of the article.
Reviews were included in the analysis because,while it is relatively "easy" to write a review, it is very difficult to write a review that is well-cited. Well-cited reviews tend to be authored by leaders in the field and present conceptual advances or new hypotheses that can be as important as experimental advances. While the underlying paper-level data were provided by WoS extracts, the author-specific tabulations of number of papers, "broad impact" citations (see below for further discussion), total citations, and Hindex were achieved through the use of the Thomson Reuters HistCite software package [9] . HistCite facilitates author-level bibliometric analysis within a given literature base.
Full names for the PD researchers in this study were derived from the publicly-available BiomedExperts [10] repository, which allows for the accurate extraction of full names (i.e., last name, first name, middle initial) through author-disambiguation algorithms. While powerful, it was clear during the analysis that the automated, author-disambiguation routines used in assigning papers to the individual scientists are not perfect, so manual checking was used in addition. The metrics, therefore, represent a good approximation of impact and productivity rather than an exact measurement.
BiomedExperts.com was also utilized in determining each scientist's main line of investigation. The top five MeSH terms from each investigator's research profile in BiomedExperts were considered. The highest-ranked MeSH term within the top five for a given scientist that could be considered a PD line of investigation was chosen as the main line of investigation for the researcher in question. It is important to note that the papers used to generate the top five MeSH terms for each scientist were not restricted to those papers mentioning PD, but were taken from a collection of PubMed papers representative of an investigator's entire corpus of published work. It follows, then, that the line of investigation chosen for each researcher is not necessarily the line of investigation most frequently found within that scientist's PD papers. The MeSH term chosen is, however, one that the scientist has applied to their PD research and, more importantly, is the line of investigation most representative of the entire research portfolio of the investigator in question. This approach to line-of-investigation identification, while not always completely accurate, allows a broad picture of the areas of expertise of the most cited researchers within the world of PD research without attempting to compare competing MeSH-term frequencies within an investigator's PD-specific paper corpus. As part of the total-citations analysis, the new metric, "broad impact citations", is used as a measure of a given investigator's impact beyond the PD research community. In the broad-impact ranking, only the subset of an investigator's citations which originate from references in papers that are not part of this analysis (i.e. papers which fall outside of the PD literature) are considered.
For the 21 st century ranking, the same methods and considerations were applied to the data collection and analysis as described for the post-1984 total-citations ranking. The only difference is the temporal filter applied, which, for the 21 st century ranking, was PD papers published and indexed in WoS between 2001 and 2010.
RESULTS

Productivity and impact among PD investigatorsthe three metrics
As a first step in determining which PD investigators have contributed the most to the field since 1985, an article corpus was generated comprising 40,152 papers written in 21 languages appearing in 2,387 journals by authors representing 108 countries. From this corpus, a pool of the 300 most-cited PD researchers was generated. Those investigators who had five or fewer PD papers were excluded from the analysis. For each author in the pool of the 300 most-cited investigators, H-indices, total paper counts, "broad impact" citations Table 3 Authors with highest H-indices calculated from same document base as used for the total-citation tabulations in Table 1 (see the section below), and total citations were calculated. Finally top-100 rankings for total citations and H-Index were generated.
Further refining impact measures -broad impact citations
Because of the increasing phenomenon of advances having implications beyond a particular disease, part of the analysis was dedicated to evaluating methods of differentiating, algorithmically, those authors who contribute work that has impact beyond the PD community. One datum generated by HistCite is the number of "internal" citations an author has generated within a given set of papers. Applying the concept of internal citations to the PD literature under analysis, one is able to split each investigator's citations into those citations accrued from papers within the PD literature and those citations arising from references in papers outside of the PD literature. It thus becomes possible to calculate how many citations a given investigator has if only citations from papers outside the PD literature were Isacson, Ole Harvard University 2,331 n/a n/a Table 1  rank to Table 4 20 languages appearing in 1,740 journals by authors representing 97 countries. Tables 1-3 will be clearly recognized by the majority of PD investigators as being "superstars" (for example the late David Marsden) in the PD community. By contrast, however, many of the investigators appearing in Table 4 are likely to be less well known. The appearance of such names in a top-100 PD ranking is evidence that there are a considerable number of "rising stars" who, in the last decade, have made significant contributions to the PD literature, often through molecular or genetic approaches. Given the more modern nature of their lines of investigation, these investigators are not nearly as prominent when studying a longer timeframe.
CONCLUSIONS
Most names in
An interesting direction for future study that naturally follows the work presented in this paper would be a more in depth examination of those areas of basic science which have contributed heavily to the current understanding of PD. An example of this would be to attempt to quantify the degree to which genomics or studies of mitochondrial dysfunction and oxidative stress have inspired new lines of investigation within the PD research community.
